Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Respiratory system drug stubs
Olopatadine/mometasone
Другие языки:

    Olopatadine/mometasone

    Подписчиков: 0, рейтинг: 0

    Olopatadine/mometasone
    Combination of
    Olopatadine Selective histamine H1-receptor antagonist
    Mometasone Corticosteroid
    Clinical data
    Trade names Ryaltris
    Other names GSP 301
    License data
    Pregnancy
    category
    • AU: B3
    Routes of
    administration    		 Nasal spray
    ATC code
    • None
    Legal status
    Legal status
    Identifiers
    KEGG

    Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. It contains olopatadine hydrochloride and mometasone furoate monohydrate. It is sprayed into the nose.

    Common side effects include an unpleasant taste (dysgeusia).

    It was approved for medical use in Australia in December 2019, and in the United States in January 2022.

    External links

    • "Olopatadine". Drug Information Portal. U.S. National Library of Medicine.
    • "Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.
    • Clinical trial number NCT02631551 for "Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-301)" at ClinicalTrials.gov
    • Clinical trial number NCT02870205 for "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (GSP 301-304)" at ClinicalTrials.gov



    Новое сообщение